<DOC>
	<DOCNO>NCT01338753</DOCNO>
	<brief_summary>The purpose study compare association image certain molecular marker complete response patient locally advance breast cancer , treat neoadjuvant chemotherapy compose Bevacizumab , Docetaxel Doxorubicin .</brief_summary>
	<brief_title>Study Evaluate Markers Response Locally Advanced Breast Cancer</brief_title>
	<detailed_description>This pharmacogenomic phase II , multicenter , prospective clinical trial whose main objective evaluate association molecular image marker response bevacizumab administration combination docetaxel doxorubicin neoadjuvant chemotherapy patient diagnose locally advanced breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female Signed Informed consent form Ages 18 70 12 month life expectancy least Histologically confirm breast cancer No previous treatment locally advance breast cancer Her2+ Her2 Disease measurable PET and/or MRI ECOG 01 Adequate organic function Negative pregnancy test ; fertile woman must use anticonceptive method ICF 30 day last study drug administration Enough capability follow procedure followup test include protocol Metastatic disease Inadequate health receive study chemotherapy Previous breast cancer treatment Pregnant lactate woman Major surgery significative traumatic injure 28 day previous inclusion , treatment . Minor surgery 24 hour first bevacizumab infusion Concomitant recent aspirin ( &gt; 325mg/day ) clopidogrel ( &gt; 75mg/day ) treatment Concomitant recent oral anticoagulant treatment History evidence bleed diathesis hereditary coagulopathy bleed risk Uncontrolled arterial hypertension Clinical significative heart disease , uncontrolled severe arrhythmia disorder Unhealed wound , peptic ulcer bone fracture History abdominal fistula , gastrointestinal perforation intrabdominal abscess , 6 month inclusion Evidence disease , neurological metabolical disorder physical examination laboratory find related disease make subjet ineligible study treatment put subject risk study treatment . Psychiatric disorder may prevent subject complete study treatment Current participation trial involve investigational drug , participation kind trial 28 day inclusion Chronical corticosteroid treatment Hypersensitivity reaction bevacizumab component study drug component Patients diagnose different neoplasms previous 5 year exclude non melanoma skin cancer resect cervical cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
	<keyword>Pharmacogenomics</keyword>
	<keyword>bevacizumab</keyword>
</DOC>